Corrigendum to “Fixed-dose combination of indacaterol/glycopyrronium/mometasone furoate once-daily versus salmeterol/fluticasone twice-daily plus tiotropium once-daily in patients with uncontrolled asthma: A randomised, Phase IIIb, non-inferiority study (ARGON)” [Respir. Med. 170 (Aug-Sep 2020) 106021] (Respiratory Medicine (2020) 170, (S095461112030161X), (10.1016/j.rmed.2020.106021))

Christian Gessner; Oliver Kornmann; Jorge Maspero; Richard van Zyl-Smit; Matthias Krüll; Anna Saliņa; Pritam Gupta; Sebastien Bostel; Sebastian Fucile; Lorena Garcia Conde; Pascal Pfister

doi:10.1016/j.rmed.2020.106186

Corrigendum to “Fixed-dose combination of indacaterol/glycopyrronium/mometasone furoate once-daily versus salmeterol/fluticasone twice-daily plus tiotropium once-daily in patients with uncontrolled asthma: A randomised, Phase IIIb, non-inferiority study (ARGON)” [Respir. Med. 170 (Aug-Sep 2020) 106021] (Respiratory Medicine (2020) 170, (S095461112030161X), (10.1016/j.rmed.2020.106021))

Christian Gessner (Corresponding Author)
, Oliver Kornmann
, Jorge Maspero
, Richard van Zyl-Smit
, Matthias Krüll
, Anna Saliņa
, Pritam Gupta
, Sebastien Bostel
, Sebastian Fucile
, Lorena Garcia Conde
, Pascal Pfister

Research output: Contribution to journal › Comment/debate

3 Citations (Scopus)

Abstract

Two instances of data have been updated in Table 2 (Page 8) of the publication, following an amendment in the Clinical Study Report. Asthma (severe exacerbation) data in the column of IND/GLY/MF high-dose o.d. (N = 476) changed from 2 (0.4) to 3 (0.6) and added data on Supraventricular tachycardia: IND/GLY/MF medium-dose o.d., 0; IND/GLY/MF high-dose o.d., 1 (0.2); SAL/FLU high-dose b. i.d.+TIO o. d. 0. This update to the safety section/table does not affect the overall results and conclusion presented in this publication.

Original language	English
Article number	106186
Journal	Respiratory Medicine
Volume	175
DOIs	https://doi.org/10.1016/j.rmed.2020.106186
Publication status	Published - Dec 2020
Externally published	Yes

Field of Science*

3.2 Clinical medicine

Publication Type*

1.1. Scientific article indexed in Web of Science and/or Scopus database

Access to Document

10.1016/j.rmed.2020.106186

Corrigendum toFinal published version, 229 KBLicence: Other

Fingerprint

Dive into the research topics of 'Corrigendum to “Fixed-dose combination of indacaterol/glycopyrronium/mometasone furoate once-daily versus salmeterol/fluticasone twice-daily plus tiotropium once-daily in patients with uncontrolled asthma: A randomised, Phase IIIb, non-inferiority study (ARGON)” [Respir. Med. 170 (Aug-Sep 2020) 106021] (Respiratory Medicine (2020) 170, (S095461112030161X), (10.1016/j.rmed.2020.106021))'. Together they form a unique fingerprint.

Cite this

Gessner, C., Kornmann, O., Maspero, J., van Zyl-Smit, R., Krüll, M., Saliņa, A., Gupta, P., Bostel, S., Fucile, S., Conde, L. G., & Pfister, P. (2020). Corrigendum to “Fixed-dose combination of indacaterol/glycopyrronium/mometasone furoate once-daily versus salmeterol/fluticasone twice-daily plus tiotropium once-daily in patients with uncontrolled asthma: A randomised, Phase IIIb, non-inferiority study (ARGON)” [Respir. Med. 170 (Aug-Sep 2020) 106021] (Respiratory Medicine (2020) 170, (S095461112030161X), (10.1016/j.rmed.2020.106021)). Respiratory Medicine, 175, Article 106186. https://doi.org/10.1016/j.rmed.2020.106186

Gessner, Christian ; Kornmann, Oliver ; Maspero, Jorge et al. / Corrigendum to “Fixed-dose combination of indacaterol/glycopyrronium/mometasone furoate once-daily versus salmeterol/fluticasone twice-daily plus tiotropium once-daily in patients with uncontrolled asthma : A randomised, Phase IIIb, non-inferiority study (ARGON)” [Respir. Med. 170 (Aug-Sep 2020) 106021] (Respiratory Medicine (2020) 170, (S095461112030161X), (10.1016/j.rmed.2020.106021)). In: Respiratory Medicine. 2020 ; Vol. 175.

@article{bbcdb9b41c9e40758f385624e10ff01d,

title = "Corrigendum to “Fixed-dose combination of indacaterol/glycopyrronium/mometasone furoate once-daily versus salmeterol/fluticasone twice-daily plus tiotropium once-daily in patients with uncontrolled asthma: A randomised, Phase IIIb, non-inferiority study (ARGON)” [Respir. Med. 170 (Aug-Sep 2020) 106021] (Respiratory Medicine (2020) 170, (S095461112030161X), (10.1016/j.rmed.2020.106021))",

abstract = "Two instances of data have been updated in Table 2 (Page 8) of the publication, following an amendment in the Clinical Study Report. Asthma (severe exacerbation) data in the column of IND/GLY/MF high-dose o.d. (N = 476) changed from 2 (0.4) to 3 (0.6) and added data on Supraventricular tachycardia: IND/GLY/MF medium-dose o.d., 0; IND/GLY/MF high-dose o.d., 1 (0.2); SAL/FLU high-dose b. i.d.+TIO o. d. 0. This update to the safety section/table does not affect the overall results and conclusion presented in this publication.",

author = "Christian Gessner and Oliver Kornmann and Jorge Maspero and \{van Zyl-Smit\}, Richard and Matthias Kr{\"u}ll and Anna Saliņa and Pritam Gupta and Sebastien Bostel and Sebastian Fucile and Conde, \{Lorena Garcia\} and Pascal Pfister",

note = "Publisher Copyright: {\textcopyright} 2020 Elsevier Ltd",

year = "2020",

month = dec,

doi = "10.1016/j.rmed.2020.106186",

language = "English",

volume = "175",

journal = "Respiratory Medicine",

issn = "0954-6111",

publisher = "W.B. Saunders Ltd",

}

Gessner, C, Kornmann, O, Maspero, J, van Zyl-Smit, R, Krüll, M, Saliņa, A, Gupta, P, Bostel, S, Fucile, S, Conde, LG & Pfister, P 2020, 'Corrigendum to “Fixed-dose combination of indacaterol/glycopyrronium/mometasone furoate once-daily versus salmeterol/fluticasone twice-daily plus tiotropium once-daily in patients with uncontrolled asthma: A randomised, Phase IIIb, non-inferiority study (ARGON)” [Respir. Med. 170 (Aug-Sep 2020) 106021] (Respiratory Medicine (2020) 170, (S095461112030161X), (10.1016/j.rmed.2020.106021))', Respiratory Medicine, vol. 175, 106186. https://doi.org/10.1016/j.rmed.2020.106186

Corrigendum to “Fixed-dose combination of indacaterol/glycopyrronium/mometasone furoate once-daily versus salmeterol/fluticasone twice-daily plus tiotropium once-daily in patients with uncontrolled asthma: A randomised, Phase IIIb, non-inferiority study (ARGON)” [Respir. Med. 170 (Aug-Sep 2020) 106021] (Respiratory Medicine (2020) 170, (S095461112030161X), (10.1016/j.rmed.2020.106021)). / Gessner, Christian (Corresponding Author); Kornmann, Oliver; Maspero, Jorge et al.
In: Respiratory Medicine, Vol. 175, 106186, 12.2020.

Research output: Contribution to journal › Comment/debate

TY - JOUR

T1 - Corrigendum to “Fixed-dose combination of indacaterol/glycopyrronium/mometasone furoate once-daily versus salmeterol/fluticasone twice-daily plus tiotropium once-daily in patients with uncontrolled asthma

T2 - A randomised, Phase IIIb, non-inferiority study (ARGON)” [Respir. Med. 170 (Aug-Sep 2020) 106021] (Respiratory Medicine (2020) 170, (S095461112030161X), (10.1016/j.rmed.2020.106021))

AU - Gessner, Christian

AU - Kornmann, Oliver

AU - Maspero, Jorge

AU - van Zyl-Smit, Richard

AU - Krüll, Matthias

AU - Saliņa, Anna

AU - Gupta, Pritam

AU - Bostel, Sebastien

AU - Fucile, Sebastian

AU - Conde, Lorena Garcia

AU - Pfister, Pascal

PY - 2020/12

Y1 - 2020/12

N2 - Two instances of data have been updated in Table 2 (Page 8) of the publication, following an amendment in the Clinical Study Report. Asthma (severe exacerbation) data in the column of IND/GLY/MF high-dose o.d. (N = 476) changed from 2 (0.4) to 3 (0.6) and added data on Supraventricular tachycardia: IND/GLY/MF medium-dose o.d., 0; IND/GLY/MF high-dose o.d., 1 (0.2); SAL/FLU high-dose b. i.d.+TIO o. d. 0. This update to the safety section/table does not affect the overall results and conclusion presented in this publication.

AB - Two instances of data have been updated in Table 2 (Page 8) of the publication, following an amendment in the Clinical Study Report. Asthma (severe exacerbation) data in the column of IND/GLY/MF high-dose o.d. (N = 476) changed from 2 (0.4) to 3 (0.6) and added data on Supraventricular tachycardia: IND/GLY/MF medium-dose o.d., 0; IND/GLY/MF high-dose o.d., 1 (0.2); SAL/FLU high-dose b. i.d.+TIO o. d. 0. This update to the safety section/table does not affect the overall results and conclusion presented in this publication.

UR - https://www.scopus.com/pages/publications/85092943068

U2 - 10.1016/j.rmed.2020.106186

DO - 10.1016/j.rmed.2020.106186

M3 - Comment/debate

C2 - 33082033

AN - SCOPUS:85092943068

SN - 0954-6111

VL - 175

JO - Respiratory Medicine

JF - Respiratory Medicine

M1 - 106186

ER -

Gessner C, Kornmann O, Maspero J, van Zyl-Smit R, Krüll M, Saliņa A et al. Corrigendum to “Fixed-dose combination of indacaterol/glycopyrronium/mometasone furoate once-daily versus salmeterol/fluticasone twice-daily plus tiotropium once-daily in patients with uncontrolled asthma: A randomised, Phase IIIb, non-inferiority study (ARGON)” [Respir. Med. 170 (Aug-Sep 2020) 106021] (Respiratory Medicine (2020) 170, (S095461112030161X), (10.1016/j.rmed.2020.106021)). Respiratory Medicine. 2020 Dec;175:106186. doi: 10.1016/j.rmed.2020.106186